Does VALGANCICLOVIR Cause Hyperparathyroidism secondary? 28 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Hyperparathyroidism secondary have been filed in association with VALGANCICLOVIR (VALGANCICLOVIR). This represents 0.4% of all adverse event reports for VALGANCICLOVIR.
28
Reports of Hyperparathyroidism secondary with VALGANCICLOVIR
0.4%
of all VALGANCICLOVIR reports
0
Deaths
27
Hospitalizations
How Dangerous Is Hyperparathyroidism secondary From VALGANCICLOVIR?
Of the 28 reports, 27 (96.4%) required hospitalization.
Is Hyperparathyroidism secondary Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VALGANCICLOVIR. However, 28 reports have been filed with the FAERS database.
What Other Side Effects Does VALGANCICLOVIR Cause?
Off label use (1,882)
Cytomegalovirus infection (1,091)
Drug ineffective (886)
Neutropenia (809)
Leukopenia (574)
Drug resistance (524)
Cytomegalovirus viraemia (447)
Pancytopenia (434)
Cytomegalovirus infection reactivation (374)
Death (359)
What Other Drugs Cause Hyperparathyroidism secondary?
ESOMEPRAZOLE (1,357)
OMEPRAZOLE (1,274)
PANTOPRAZOLE (947)
LANSOPRAZOLE (888)
DEXLANSOPRAZOLE (382)
RABEPRAZOLE (108)
DENOSUMAB (60)
FUROSEMIDE (49)
OMEPRAZOLE\SODIUM BICARBONATE (48)
ESOMEPRAZOLE\NAPROXEN (47)
Which VALGANCICLOVIR Alternatives Have Lower Hyperparathyroidism secondary Risk?
VALGANCICLOVIR vs VALIUM
VALGANCICLOVIR vs VALPROATE
VALGANCICLOVIR vs VALPROIC ACID
VALGANCICLOVIR vs VALPROMIDE
VALGANCICLOVIR vs VALSARTAN